Drug Trial News

RSS

Seaside reports positive data from STX209 Phase 2 study in ASD

Seaside Therapeutics, Inc. announced today positive data from an open-label Phase 2 study of STX209 conducted in patients with autism spectrum disorders (ASD). The primary endpoint of the study, an improvement on the Irritability subscale of the Aberrant Behavior Checklist (ABC-I), achieved statistical significance (p<0.001).

9 Sep 2010

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc, the global specialty biopharmaceutical company, today announced a joint development and commercialization agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway. This pathway plays critical roles in regulating the growth of skeletal muscle.

9 Sep 2010

DARA BioSciences presents KRN5500 study results at World Congress on Pain

DARA BioSciences announced today that it presented study results from its Phase 2 multicenter, placebo controlled, double-blind, randomized dose escalation study for KRN5500 at the 13th World Congress on Pain held recently in Montreal.

9 Sep 2010

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.

9 Sep 2010

Researchers find minocycline antibiotics effective for fragile X syndrome

One of the antibiotics most commonly prescribed to treat adolescent acne can increase attention spans and communication and decrease anxiety in patients with fragile X syndrome, the most common inherited cause of mental impairment, according to a new survey study that is the first published on parents' reports of their children's responses to treatment with the medication.

9 Sep 2010

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will deliver four poster presentations on its compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

9 Sep 2010

Insulin may reduce life-threatening bacterial infections in intensive care patients

Treating intensive care patients who develop life-threatening bacterial infections, or septicemia, with insulin potentially could reduce their chances of succumbing to the infection, if results of a new preliminary study can be replicated in a larger study.

9 Sep 2010

Team of scientists issues HIV vaccine strategy

The Council of the Global HIV Vaccine Enterprise on Tuesday released a new strategy for HIV vaccine research, which marked "the culmination of an 18-month effort that included the input of 400 scientists worldwide," VOA News reports (DeCapua, 9/7).

9 Sep 2010

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA, being held September 12 -15 at the Boston Convention and Exhibition Center.

9 Sep 2010

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

Hemispherx Biopharma, Inc. will present new clinical data on the possible inter-relationships of XMRV positivity/chronic fatigue syndrome/Ampligen responsiveness at the 1st International Workshop on XMRV being held at the National Institutes of Health in Bethesda, MD, on September 7 and 8, 2010.

9 Sep 2010

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

9 Sep 2010

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

EDAP TMS SA, the global leader in therapeutic ultrasound, today reported favorable clinical outcomes for patients treated with Ablatherm-HIFU.

9 Sep 2010

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Nevirapine is widely used to help prevent mother-to-child transmission of the HIV virus. In cases where the infants are nonetheless infected with HIV virus at birth, the standard treatment is to use protease inhibitors (PI) to reduce the amount of virus in their bloodstream. A new study involving 195 infants in South Africa found that children who were treated with PI and then switched to nevirapine were more likely to maintain virus below the detection threshold of the test than infants who continued to receive PI.

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.

9 Sep 2010

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology. Flutemetamol is an investigational positron emission tomography (PET) imaging agent being developed by GE Healthcare, in the field of brain imaging.

9 Sep 2010

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.

8 Sep 2010

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.

8 Sep 2010

Drug Trial News

Seaside reports positive data from STX209 Phase 2 study in ASD

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

DARA BioSciences presents KRN5500 study results at World Congress on Pain

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Researchers find minocycline antibiotics effective for fragile X syndrome

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

Insulin may reduce life-threatening bacterial infections in intensive care patients

Team of scientists issues HIV vaccine strategy

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News